(NASDAQ: BTAI) Bioxcel Therapeutics's forecast annual revenue growth rate of 411.74% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.29%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.95%.
Bioxcel Therapeutics's revenue in 2026 is $680,000.On average, 7 Wall Street analysts forecast BTAI's revenue for 2026 to be $30,235,351, with the lowest BTAI revenue forecast at $23,300,241, and the highest BTAI revenue forecast at $36,003,287. On average, 6 Wall Street analysts forecast BTAI's revenue for 2027 to be $878,406,107, with the lowest BTAI revenue forecast at $628,791,548, and the highest BTAI revenue forecast at $1,134,751,984.
In 2028, BTAI is forecast to generate $3,149,515,710 in revenue, with the lowest revenue forecast at $3,026,005,290 and the highest revenue forecast at $3,242,148,525.